DZ2595A1 - Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs et procédépour leur préparation. - Google Patents

Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs et procédépour leur préparation.

Info

Publication number
DZ2595A1
DZ2595A1 DZ980205A DZ980205A DZ2595A1 DZ 2595 A1 DZ2595 A1 DZ 2595A1 DZ 980205 A DZ980205 A DZ 980205A DZ 980205 A DZ980205 A DZ 980205A DZ 2595 A1 DZ2595 A1 DZ 2595A1
Authority
DZ
Algeria
Prior art keywords
atorvastatin
combinations
preparation
pharmaceutical compositions
antihypertensive agents
Prior art date
Application number
DZ980205A
Other languages
English (en)
French (fr)
Inventor
Robert Andrew Donald Scott
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DZ2595A1 publication Critical patent/DZ2595A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Pyrrole Compounds (AREA)
DZ980205A 1997-08-29 1998-08-26 Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs et procédépour leur préparation. DZ2595A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5727697P 1997-08-29 1997-08-29

Publications (1)

Publication Number Publication Date
DZ2595A1 true DZ2595A1 (fr) 2003-02-22

Family

ID=22009602

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980205A DZ2595A1 (fr) 1997-08-29 1998-08-26 Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs et procédépour leur préparation.

Country Status (41)

Country Link
US (2) US20020099046A1 (bg)
EP (1) EP1009400B1 (bg)
JP (2) JP2001514223A (bg)
KR (3) KR20030015394A (bg)
CN (3) CN1473566A (bg)
AP (1) AP1191A (bg)
AR (1) AR016399A1 (bg)
AT (1) ATE285767T1 (bg)
AU (1) AU740424B2 (bg)
BG (1) BG64724B1 (bg)
BR (1) BR9811556A (bg)
CA (1) CA2296723A1 (bg)
CO (1) CO4970724A1 (bg)
DE (1) DE69828413T2 (bg)
DZ (1) DZ2595A1 (bg)
EA (1) EA200000012A1 (bg)
EG (1) EG24678A (bg)
ES (1) ES2234134T3 (bg)
GT (1) GT199800126A (bg)
HR (1) HRP980474A2 (bg)
HU (1) HUP0004318A3 (bg)
ID (1) ID24118A (bg)
IL (2) IL133962A0 (bg)
IS (1) IS5341A (bg)
MA (1) MA26536A1 (bg)
MY (1) MY121008A (bg)
NO (1) NO323987B1 (bg)
NZ (2) NZ502280A (bg)
OA (1) OA11291A (bg)
PA (1) PA8457901A1 (bg)
PE (1) PE107099A1 (bg)
PL (1) PL339091A1 (bg)
PT (1) PT1009400E (bg)
SA (1) SA98190603B1 (bg)
SK (1) SK1432000A3 (bg)
TN (1) TNSN98155A1 (bg)
TR (1) TR200000563T2 (bg)
UY (1) UY25155A1 (bg)
WO (1) WO1999011260A1 (bg)
YU (1) YU2000A (bg)
ZA (1) ZA987839B (bg)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
AU1591699A (en) * 1998-03-17 1999-10-11 Warner-Lambert Company Statin-matrix metalloproteinase inhibitor combinations
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AU2007200367B2 (en) * 1999-02-06 2010-04-08 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
US7125897B1 (en) 1999-09-24 2006-10-24 Vasogen Ireland Limited Combined therapies for atherosclerosis treatment
FR2803525B1 (fr) * 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
AR032758A1 (es) 2000-07-19 2003-11-26 Novartis Ag Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos
WO2002017913A1 (fr) * 2000-08-30 2002-03-07 Sankyo Company, Limited Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
OA12983A (en) * 2001-07-19 2006-10-13 Pharmacia Corp Combination of an aldosterone receptor antagonist and an HMG COA reductase inhibitor.
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AU2003278896B2 (en) * 2002-06-20 2009-10-01 The Governors Of The University Of Alberta Dichloroacetate in combination with cardioprotective or hemodynamic drugs
WO2004002472A1 (en) * 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
CN103254114A (zh) * 2002-06-27 2013-08-21 史密斯克莱.比奇曼（科克）有限公司 卡维地洛磷酸盐和/或其溶剂合物相应的组合物和/或治疗方法
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
AU2003274004A1 (en) * 2002-10-16 2004-05-04 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005051322A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
US7750036B2 (en) * 2003-11-25 2010-07-06 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
KR20050092519A (ko) * 2004-03-16 2005-09-22 화이자 인코포레이티드 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
EP1734958A1 (en) * 2004-04-06 2006-12-27 Merck & Co., Inc. Methods for the treatment of hypertension
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
CN104958270A (zh) 2004-08-25 2015-10-07 伊森舍丽斯有限公司 钾atp通道开放剂的药物制剂及其应用
EP1848425B1 (en) * 2005-02-17 2011-08-17 CHIESI FARMACEUTICI S.p.A. Therapeutic combinations of manidi pine and simvastatin
KR101381076B1 (ko) 2006-03-29 2014-04-02 코와 가부시키가이샤 트리글리세리드 저하제 및 고인슐린 혈증 개선제
US8642083B2 (en) * 2006-10-30 2014-02-04 Hanall Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
EP2281557A4 (en) 2008-04-29 2011-08-31 Hanall Biopharma Co Ltd PHARMACEUTICAL FORMULATION CONTAINING AN ANGIOTENSIN II RECEPTOR BLOCKING AGENT
CZ2008740A3 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
CN102292085B (zh) * 2009-01-23 2017-01-18 韩美科学株式会社 包含氨氯地平和氯沙坦的固体药物组合物及其制备方法
SI23149A (sl) * 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
RU2481124C1 (ru) * 2011-10-27 2013-05-10 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
CN102671198A (zh) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 一种降压降脂复方药及其制备方法
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
JP2016514125A (ja) * 2013-03-12 2016-05-19 エルジー・ライフ・サイエンシーズ・リミテッドＬＧ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． バルサルタン及びロスバスタチンカルシウムを含む複合製剤及びその製造方法
CN104173420A (zh) * 2013-05-20 2014-12-03 广州诺氏刘生物科技有限公司 一种治疗急性肾衰竭的药物
UA122778C2 (uk) 2014-10-23 2021-01-06 Арена Фармасьютікалз, Інк. Спосіб лікування станів, пов'язаних з рецептором pgi2
RU2724338C2 (ru) * 2015-06-30 2020-06-23 Ханми Фарм. Ко., Лтд. Фармацевтическая комплексная композиция, включающая амлодипин, лозартан и розувастатин
FR3040303B1 (fr) * 2015-08-27 2019-04-05 Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
CN105232555A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
WO2017210467A1 (en) * 2016-06-02 2017-12-07 Ana Pharmaceuticals, Inc. Methods and compositions for treatment of hypercalciuria and nephrolithiasis
MX2019008813A (es) 2017-01-25 2020-02-12 The George Inst For Global Health Composiciones para el tratamiento de la hipertension.
CN110582271B (zh) 2017-03-01 2022-06-14 阿瑞那制药公司 包含pgi2受体激动剂的组合物及其制备方法
BR112021001374A2 (pt) * 2018-07-26 2021-07-06 The George Inst For Global Health composições para o tratamento da hipertensão
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
ES2279526T3 (es) * 1995-11-02 2007-08-16 Warner-Lambert Company Llc Metodo y composicion farmaceutica para regular la concentracion de lipidos.

Also Published As

Publication number Publication date
JP2005041875A (ja) 2005-02-17
ES2234134T3 (es) 2005-06-16
CN1473566A (zh) 2004-02-11
AU740424B2 (en) 2001-11-01
WO1999011260A1 (en) 1999-03-11
ID24118A (id) 2000-07-06
GT199800126A (es) 2000-01-29
PL339091A1 (en) 2000-12-04
US20030199492A1 (en) 2003-10-23
CO4970724A1 (es) 2000-11-07
JP2001514223A (ja) 2001-09-11
AP9801332A0 (en) 1998-09-30
YU2000A (sh) 2002-12-10
NO323987B1 (no) 2007-07-30
ATE285767T1 (de) 2005-01-15
KR20030015394A (ko) 2003-02-20
NZ502280A (en) 2002-11-26
KR20040106591A (ko) 2004-12-17
PE107099A1 (es) 1999-11-06
MA26536A1 (fr) 2004-12-20
EA200000012A1 (ru) 2000-08-28
SA98190603B1 (ar) 2006-07-04
AR016399A1 (es) 2001-07-04
EP1009400A1 (en) 2000-06-21
NO20000996D0 (no) 2000-02-28
HUP0004318A2 (hu) 2001-05-28
HUP0004318A3 (en) 2002-10-28
KR20010022477A (ko) 2001-03-15
CN1473567A (zh) 2004-02-11
CA2296723A1 (en) 1999-03-11
AP1191A (en) 2003-07-19
MY121008A (en) 2005-12-30
BG64724B1 (bg) 2006-01-31
NZ530630A (en) 2005-05-27
DE69828413D1 (de) 2005-02-03
TNSN98155A1 (fr) 2005-03-15
TR200000563T2 (tr) 2000-07-21
EG24678A (en) 2010-04-27
BR9811556A (pt) 2000-08-22
ZA987839B (en) 2000-02-28
IL133962A (en) 2006-07-05
IS5341A (is) 2000-01-14
OA11291A (en) 2003-08-25
AU8458998A (en) 1999-03-22
PA8457901A1 (es) 2000-05-24
IL133962A0 (en) 2001-04-30
US20020099046A1 (en) 2002-07-25
EP1009400B1 (en) 2004-12-29
CN1268053A (zh) 2000-09-27
SK1432000A3 (en) 2000-12-11
HRP980474A2 (en) 1999-06-30
NO20000996L (no) 2000-04-27
PT1009400E (pt) 2005-02-28
DE69828413T2 (de) 2005-12-08
BG104075A (bg) 2000-09-29
UY25155A1 (es) 2000-12-29

Similar Documents

Publication Publication Date Title
DZ2595A1 (fr) Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs et procédépour leur préparation.
DZ2596A1 (fr) Associations pharmaceutiques d'amlodipine et d'atorvastatine et procédé pour leur préparation.
DZ2600A1 (fr) Associations pharmaceutiques d'amlodipine et d'unestatine et procédé pour leur préparation.
DZ2745A1 (fr) BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2407A1 (fr) Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
DZ2394A1 (fr) Dérivés de quinoléine et dérivés de quinazoline nouveax procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2410A1 (fr) Dérivés d'acide arylsulfonylaminohydroxamique procédé pour leur préparation et compositions pharmaceutiques
DZ2300A1 (fr) Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr) Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2197A1 (fr) Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2758A1 (fr) Dérivés bicycliques d0acide hydroxamique nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2666A1 (fr) Dérivés d'acide hydroxamique compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2186A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'ostéoporose et procédé pour leur préparation.
DZ2303A1 (fr) Dérivés d'indazole nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2523A1 (fr) Formulations pharmaceutiques contenant du voriconazole et procédé pour leur préparation.
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2923A1 (fr) Formulations pharmaceutiques d'inhibiteurs de pde-5 de gmpc à libération contrôlée, et procédé pour leur préparation.
DZ1958A1 (fr) Composés inhibiteurs de l'enzyme l-lpa compositionpharmaceutiques les composant et procédés pour leur préparation.
DZ2594A1 (fr) Dérivés de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant.
IL112664A (en) 4-amino derivatives of mycophenolic acid their preparation and pharmaceutical compositions containing them
DZ2188A1 (fr) Dérivés de quinoxalinedone, procédés et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant.
PT907364E (pt) Composicao farmaceutica de libertacao sustida
DZ2550A1 (fr) Dérivés d'azétidinylpropylpipéridine procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2414A1 (fr) 2-amino-6-(2-substitué-4-phenoxy)substituté-pyridines procédé pour leur préparation et compositions pharmaceutiques les contenant.